Jazeta (Sitagliptin Hydrochloride)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which normally degrades the incretin hormones GLP‑1 and GIP. Inhibition raises endogenous incretin levels, leading to glucose‑dependent insulin release and reduced glucagon secretion, thereby lowering both fasting and post‑prandial blood glucose.

The appropriate dose of Jazeta is determined by the prescribing clinician based on the individual’s renal function, glycemic targets and concomitant therapies. Patients should follow the exact dosing instructions provided by their healthcare provider and not adjust the dose on their own.

Safety data for sitagliptin during pregnancy and lactation are limited. It is generally not recommended for use in pregnant or breastfeeding women unless the potential benefit outweighs the potential risk, and only under close medical supervision.

To order Jazeta, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jazeta (sitagliptin) belongs to the DPP‑4 inhibitor class, offering oral glucose‑lowering without the weight gain associated with some sulfonylureas. Compared with GLP‑1 receptor agonists, it is taken once daily as a tablet rather than by injection, but it may be less potent in reducing HbA1c. Choice depends on patient profile, tolerability and therapeutic goals.

Store Jazeta at ambient temperature, below 25 °C, in the original blister pack or container. Protect the tablets from moisture, excessive heat and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Jazeta is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and maintain consistent timing each day for optimal effect.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe hypersensitivity reactions such as angioedema or anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or unexplained skin eruptions.

Jazeta should be avoided in individuals with a known hypersensitivity to sitagliptin or any component of the formulation. It is also contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose‑adjusted, and in those with a history of pancreatitis until the cause is clarified.